The present invention relates to a dry powder formulation suitable for inhalation comprising glycopyrrolate and magnesium stearate, wherein the glycopyrrolate is micronised and then undergoes a conditioning step, which step includes exposure to humid conditions of 30-100% RH at temperatures between 5°C to 90°C for at least 48 hours.
